Niche Drug Eluting Medlogics specializes in next generation drug eluting stent technology and coating, presenting a focused opportunity for partnerships or supply agreements in coronary artery disease treatments.

Small but Capable With 11-50 employees and in-house vertically integrated R&D and manufacturing, there is potential for agile collaboration, pilot programs, and rapid prototyping with reduced external dependencies.

Mid-market Revenue Current revenue range of 1M to 10M and a $30M funding base suggest room for strategic investments, co-development deals, or milestone-driven partnerships with larger device ecosystems.

California Footprint Based in Santa Rosa with in-house coating and manufacturing capabilities, Medlogics offers a localized supply option for U.S. hospitals and distributors seeking nearshore or domestic production.

Clinical Advantage Emphasis on safe, effective, clinically superior implantable devices creates openings for collaboration on clinical studies, regulatory support, or bundled devices with complementary cardiovascular portfolios.